Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
102 hedge funds and large institutions have $1.07B invested in Verona Pharma in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 36 increasing their positions, 33 reducing their positions, and 13 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 33
0.37% more ownership
Funds ownership: 9.89% → 10.27% (+0.37%)
3% less funds holding
Funds holding: 105 → 102 (-3)
20% less capital invested
Capital invested by funds: $1.33B → $1.07B (-$266M)
23% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 13
25% less funds holding in top 10
Funds holding in top 10: 12 → 9 (-3)
64% less call options, than puts
Call options by funds: $1.12M | Put options by funds: $3.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$23.3M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$16.4M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$15.8M |
| 4 |
Millennium Management
New York
|
+$7.72M |
| 5 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$5.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
-$10.3M |
| 2 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$8.07M |
| 3 |
PA
Perceptive Advisors
New York
|
-$7.51M |
| 4 |
Two Sigma Investments
New York
|
-$6.43M |
| 5 |
Two Sigma Advisers
New York
|
-$4.63M |
VRNA Hedge Fund Activity: Q3 2023 in Review
102 of the 6,271 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q3 2023, worth a combined $1.07B — down 20% from $1.33B a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of VRNA and 10 opened new positions — a net loss of 3 holders — while 33 trimmed existing stakes and 36 added.
The largest buyer was Janus Henderson Group, adding an estimated $23.3M. The largest seller was Ally Bridge Group, exiting entirely with an estimated $10.3M sold.
- 102 institutional investors held Verona Pharma (VRNA) as of Q3 2023, down from 105 in Q2 2023.
- Funds reported $1.07B of Verona Pharma stock for Q3 2023, down 20% quarter-over-quarter.
- 10 funds opened new Verona Pharma positions in Q3 2023 and 13 closed out, a net change of -3 holders.
- The largest Verona Pharma buyer in Q3 2023 was Janus Henderson Group, an estimated $23.3M added.
- The largest Verona Pharma seller in Q3 2023 was Ally Bridge Group, an estimated $10.3M sold.
Based on aggregated 13F filings for Q3 2023.